MARKET

ZIOP

ZIOP

ZIOPHARM Oncolgy
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.455
+0.065
+1.48%
After Hours: 4.455 0 0.00% 16:09 11/15 EST
OPEN
4.440
PREV CLOSE
4.390
HIGH
4.670
LOW
4.390
VOLUME
1.55M
TURNOVER
--
52 WEEK HIGH
7.25
52 WEEK LOW
1.560
MARKET CAP
806.49M
P/E (TTM)
6.61
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ZIOP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ZIOP News

  • ZIOPHARM Oncology, Inc. 2019 Q3 - Results - Earnings Call Presentation
  • Seeking Alpha - Article.1d ago
  • Ziopharm Oncology Presentation at the Jefferies 2019 London Healthcare Conference to be Webcast
  • GlobeNewswire.4d ago
  • ZIOPHARM Oncology, Inc. (ZIOP) CEO Dr. Laurence Cooper on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.5d ago
  • Ziopharm Oncology Inc (ZIOP) Q3 2019 Earnings Call Transcript
  • MotleyFool.com.11/08 15:30

More

Industry

Biotechnology & Medical Research
+1.49%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Name
Price
%Change

About ZIOP

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
More

Webull offers ZIOPHARM Oncology Inc. (ZIOP) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.